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We analyzed four DNAvaccines based on DENV-2 NS1: pcENS1, encoding the C-terminal from E protein plus the NS1 region; pcENS1ANC,
similar to pcENS1 plus the N-terminal sequence from NS2a (ANC); pcTPANS1, coding the t-PA signal sequence fused to NS1; and
pcTPANS1ANC, similar to pcTPANS1 plus the ANC sequence. The NS1 was detected in lysates and culture supernatants from pcTPANS1-,
pcENS1- and pcENS1ANC-transfected cells and not in cells with pcTPANS1ANC. Only the pcENS1ANC leads the expression of NS1 in plasma
membrane, confirming the importance of ANC sequence for targeting NS1 to cell surface. High levels of antibodies recognizing conformational
epitopes of NS1 were induced in mice immunized with pcTPANS1 and pcENS1, while only few pcENS1ANC-inoculated animals presented
detectable anti-NS1 IgG. Protection against DENV-2 was verified in pcTPANS1- and pcENS1-immunized mice, although the plasmid pcTPANS1
induced slight higher protective immunity. These plasmids seem to activate distinct patterns of the immune system.
© 2006 Elsevier Inc. All rights reserved.Keywords: DNA vaccine; Dengue virus; NS1; Mouse; ChallengeIntroduction
Dengue virus (DENV) is a mosquito-borne virus in the genus
Flavivirus, family Flaviviridae, consisting of four antigenically
related serotypes: DENV-1, DENV-2, DENV-3, DENV-4
(Lindenbach and Rice, 2001). Infection with these viruses can
result in a broad spectrum of effects, including a self-limiting
acute febrile illness, dengue fever (DF), which may evolve to
severe disease forms, dengue hemorrhagic fever/dengue shock
syndrome (DHF/DSS), with homeostatic and vascular perme-
ability abnormalities (Rothman, 2004). Annually, it is estimated
that 50–100 million cases of dengue occur in tropical and
subtropical regions, in which 500,000 result in the DHF/DSS,
with more than 20,000 deaths (Guzmán and Kourí, 2002).
Because of the importance of such disease, concerning mor-⁎ Corresponding author. Fax: +55 21 25903495.
E-mail address: ada@ioc.fiocruz.br (A.M.B. Alves).
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doi:10.1016/j.virol.2006.08.052bidity and mortality, the development of an effective vaccine
against DENVs has been considered a high priority by theWorld
Health Organization. One of the major difficulties associated
with DENV vaccine is attributed to observations that most of
DHF occur in individuals experiencing a secondary virus infec-
tion, which lead to the need of a safe and efficient tetravalent
vaccine (Rothman, 2004). Since traditional methodologies were
not successful, several new approaches have been proposed,
including DNA vaccines (Edelman, 2005; Kinney and Huang,
2001).
The DENV are enveloped, single-stranded, positive-sense
RNAvirus of approximately 11 kb long, which contains a single
open reading frame, encoding a polyprotein precursor that is
processed by viral and host cell proteases to produce three
structural proteins, capsid (C), premembrane/membrane (prM/
M) and envelope (E), and seven nonstructural (NS) proteins,
NS1, NS2A, NS2B, NS3, NS4A, NS4B and NS5 (Lindenbach
and Rice, 2001). Most of experimental vaccines against DENV
414 S.M. Costa et al. / Virology 358 (2007) 413–423are based on the glycoproteins E and NS1, in a lesser extent. The
E protein contains major epitopes responsible for eliciting
neutralizing antibodies (Brinton et al., 1998; Chambers et al.,
1990). However, such protein may also induce non-neutralizing
antibodies involved in the phenomenon of antibody dependent
enhancement (ADE) of the infection, which might be one of the
major factors for the increase of DHF in secondary infections
(Halstead and O'Rourke, 1977; Halstead and Deen, 2002).
The NS1 protein, in its turn, is highly immunogenic and can
also induce protection in experimental animals against different
flaviviruses (Brinton et al., 1998; Schlesinger et al., 1987).
Several reports have shown that this protein may generate
antibodies with complement fixing activity, which seems to kill
infected target cells (Schlesinger et al., 1987, 1993). Since the
NS1 is not present on the virion, antibodies against such protein
may be elicited without the risk of the ADE. The NS1 is found
in mammalian infected cells associated with plasma membrane
and also secreted into the circulation as a soluble multimer
(Flamand et al., 1999; Jacobs et al., 2000; Young et al., 2000).
Although its function is not fully elucidated, evidences suggest
that NS1 is involved in viral RNA replication (Mackenzie et al.,
1996). The mature protein is essentially hydrophilic and lacks a
membrane-spanning domain. However, during virus infection,
such protein is translocated into the endoplasmic reticulum,
using a hydrophobic signal sequence present at the C-terminal
of the E protein, and associates in homodimer forms (Falgout et
al., 1989; Pryor and Wright, 1993; Winkler et al., 1989).
Dimeric NS1 is then anchored to cell membranes, probably via
a hydrophobic sequence at N-terminal of NS2a, which appears
to act as a signal sequence for glycosyl–phosphatidylinositol
(GPI) linkage of NS1 (Jacobs et al., 2000; Pryor and Wright,
1993).
One advantage of applying DNAvaccines when compared to
other approaches is the possibility of targeting the in vivo
expressed recombinant antigen to different cell compartments.
Thus, addition of signal sequences can retain the protein in
cytosol or some sub-cellular compartments or direct it to cell
membrane or secretion into extracellular milieu (Alves et al.,
1998a; Donnelly et al., 2005; Lu et al., 2003). Therefore, the
effectiveness of these vaccines can be distinct from each other
since the different DNA construction strategy adopted may
affect antigen presentation to the host immune system and
consequently influence the elicited immune response (Alves et
al., 1999; Donnelly et al., 2005).
Based on these evidences, in the present work, we con-
structed four different DNA vaccines encoding the DENV-2
NS1 in frame with its natural signal sequence, present at the
C-terminal of the E protein, or with the secretory signal pep-
tide derived from human tissue plasminogen activator (t-PA).
Two of these constructs contained the hydrophobic stretch
derived from the NS2a protein in order to target the recom-
binant NS1 to host cell surface, while the other plasmids were
designed for protein secretion. Results demonstrated that these
constructions differed on their abilities to drive the expression
of NS1 in mammalian cells, to elicit NS1-specific antibodies in
mice and to confer protection against DENV-2 challenge in
these animals.Results
Construction of different recombinant plasmids encoding the
ns1 gene
Four different recombinant plasmids, pcTPANS1, pcTPAN-
S1ANC, pcENS1 and pcENS1ANC, were constructed as
described in Materials and methods. In the pcTPANS1 and
pcTPANS1ANC constructs, the NS1 region from DENV-2 was
cloned in framewith the t-PA signal sequence. Both plasmids are
similar, except that the coding sequence of the pcTPANS1ANC
was extended 138 nucleotides into the NS2A region (Fig. 1). The
two other plasmids, pcENS1 and pcENS1ANC, contain the
sequence of 63 nucleotides, which codes the 21 amino acid
signal peptide derived from the C-terminal of the E protein, in
addiction to the NS1 region (Fig. 1). The pcENS1ANC also
encodes the 138 nucleotides from the NS2A region, similar to
pcTPANS1ANC plasmid (Fig. 1). The t-PA signal peptide and
the C-terminal hydrophobic region of the E protein were both
used to target the translocation of the NS1 into endoplasmic
reticulum and its secretion to extracellular space.
In vitro expression of the NS1 protein
The expression of recombinant NS1 proteins was evaluated
in BHK-21 cells transiently transfected with each plasmid. Cells
transfected with pcTPANS1, pcENS1 and pcENS1ANC plas-
mids were positively stained by immunofluorescence assays
using a DENV-2 hyperimmune ascitic fluid (Fig. 2), which
indicates that these constructs promote the expression of the NS1
in eukaryotic systems. On the other hand, no reaction could be
detected in pcTPANS1ANC-transfected cell culture (Fig. 2f),
although sequencing analysis revealed that the ns1 gene was
correctly cloned in this construct. As expected, cells transfected
with control vectors (pcTPA and pcDNA3) did not react with
DENV-2 antibodies (data not shown).
The expression of NS1 promoted by pcTPANS1, pcENS1
and pcENS1ANC was confirmed by Western blot (Fig. 3). A
protein of approximately 48 kDa, corresponding to the NS1, was
detected in pcTPANS1- and pcENS1-transfected cell lysates
(Fig. 3a). In pcENS1ANC-transfected cell extract, one slight
larger NS1 form was detected (Fig. 3a), probably due to the
presence of the C-terminal hydrophobic region of 46 amino
acids from the NS2a protein. Similar to results observed in the
immunofluorescence assays, the pcTPANS1ANC-transfected
cell lysate did not present any corresponding NS1 protein,
confirming that this construct was not able to promote the
expression of such protein. As expected, no related band was
observed in cells transfected with control vectors (Fig. 3a). The
presence of the NS1 protein was also detected in culture super-
natants of pcTPANS1-, pcENS1- and pcENS1ANC-transfected
cells (Fig. 3b), which demonstrated that the signal sequences
cloned upstream the ns1 gene (the t-PA sequence and C-terminal
hydrophobic region from the E protein) indeed targeted the
recombinant protein to secretion. In order to evaluate whether
secreted NS1 was in monomeric or dimeric forms, samples were
suspended in non-reducing conditions, submitted or not to heat
Fig. 1. Schematic diagram of DENV-2 genome map and plasmid constructs. Black area represents the NS1 region; hatched boxes represent signal sequences from the
C-terminal of E protein (E) and the N-terminal of NS2a protein (ANC); open box represents the signal peptide derived from the human tissue plasminogen
activator (t-PA).
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mainly in a dimeric form of approximately 96 kDa, which be-
came monomers of approximately 48 kDa after heat denatur-
ation (Fig. 3b). A recombinant NS1 protein expressed in insect
cells was used as a positive control. Such protein presented a
slight size difference when compared to the NS1 expressed in
BHK cells (Fig. 3b), which may be due to distinct glycosylation
patterns from these two expression systems.Fig. 2. BHK-21 cells transfected with the different recombinant plasmids: pcTPANS1
permeabilized, fixed and treated with DENV-2 hyperimmune mouse ascitic flu
immunofluorescence (e–h). Magnification, ×400.The NS1 localization in transfected BHK cells by electron
microscopy
Cells transfected with pcTPANS1, pcENS1 and pcEN-
S1ANC were immunostained with DENV-2 hyperimmune
ascitic fluid and analyzed by electron microscopy in order to
localize the NS1 protein. As expected, the protein was detected
mainly in vesicles in all transfected cells, showing its targeting to(a, e), pcTPANS1ANC (b, f), pcENS1 (c, g) and pcENS1ANC (d, h). Cells were
id and anti-mouse fluorescein-conjugated goat IgG. Phase contrast (a–d);
Fig. 3. NS1 protein expressed from recombinant plasmids in transfected BHK cells and detected in Western blots of SDS-PAGE, using DENV-2 hyperimmune mouse
ascitic fluid. Samples were suspended in SDS-PAGE buffer with heat treatment (a) or in phosphate buffer with protease inhibitors without 2-mercaptoethanol,
submitted or not to heat treatment (b). (a) Whole-cell extracts harvested from transfections with pcDNA3 (lane 1), pcTPANS1 (lane 2), pcTPANS1ANC (lane 3),
pcENS1 (lane 4) and pcENS1ANC (lane 5). Arrow indicates bands corresponding to the NS1 protein. (b) Purified NS1 protein expressed in insect cells (lanes 1 and 2)
and culture supernatants harvested from cells transfected with pcTPA (lane 3), pcTPANS1 (lanes 4 and 5), pcDNA3 (lane 6), pcENS1 (lanes 7 and 8) and pcENS1ANC
(lanes 9 and 10), not submitted to heat treatment (lanes 1, 4, 7 and 9) or boiled for 5 min (lanes 2, 3, 5, 6, 8 and 10).
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pcENS1ANC, vesicles containing NS1 were seen close to and
fused with the cytoplasmic membrane, which in some parts lead
to its anchoring to the membrane on the surface of the cell (Figs.
4c and d). Such results confirm that the recombinant protein is
predominantly secreted, due to the signal peptide sequences
cloned upstream of the gene, and that the hydrophobic sequence
from the NS2a protein is essential for the NS1 association with
the plasma membrane.
Antibody response elicited in mice immunized with different
plasmids
Serum samples from mice immunized twice with one of the
recombinant plasmids were tested individually by ELISA,
4 weeks after the first DNA injection. All pcTPANS1- and
pcENS1-inoculated animals presented a significant NS1-spe-
cific antibody response, with titers ranging from 20,000 to
30,000 in both cases, except for one animal in each group, which
presented higher antibody levels (41,000 and 61,000 for
pcTPANS1- and pcENS1-immunized mice, respectively)
(Figs. 5a and b). On the other hand, only half of pcEN-
S1ANC-inoculated animals (5 in 10) presented NS1-specific
IgG response (two mice with antibody titers of approximately
1000 and three with titers ranging from 4700 to 5600) (Fig. 5c).
As expected, pcTPANS1ANC-inoculated mice did not present
any NS1-specific antibody response, as well as animals injected
with control vectors, pcTPA or pcDNA3 (data not shown).
Time course of serum NS1-specific IgG responses were then
analyzed in pooled samples from pcTPANS1- and pcENS1-
immunized groups and from the five NS1-positive mice ino-
culatedwith the pcENS1ANC. Levels of NS1-specific antibodies
were very similar in animals immunized with pcTPANS1 and
pcENS1, which attained maximum values 4 weeks after the first
DNAdose and remained stable until 10weeks after the beginning
of experiments (Fig. 6). Animals inoculated with pcENS1ANC
presented considerable lower NS1-specific antibody levels in all
time points tested (Fig. 6). However, humoral response patterns
were similar in the three immunization groups, with a significantincrease of antibody levels after the second DNA inoculation.
Epitope specificities of antibodies generated by immunization
with the three plasmids were analyzed, using intact or heat-
denatured forms of theNS1 protein as solid-phase bound antigen.
Antibodies raised in all immunizations recognized mainly the
intact form of NS1 since reactivity of antibodies was drastically
reduced when the heat-denatured protein was used (approxi-
mately 30-fold lower when compared to the non-denatured NS1
during peak antibody level) (Fig. 6). These results suggest that
antibodies induced by the three plasmids recognized mainly
conformational surface-exposed epitopes, which are practically
absent in the heat-denatured NS1 protein.
Protective immunity in pcTPANS1- and pcENS1-vaccinated
mice
Since the pcTPANS1 and pcENS1 elicited high and
homogenous NS1-specific antibody responses, they were
selected for further challenge experiments. The protective effi-
cacy of these plasmids was then evaluated in animals vaccinated
and i.c. challenged with a mouse brain adapted DENV-2,
2 weeks after the second DNA dose, when peak antibody levels
were observed. As controls, mice inoculated with pcTPA or
pcDNA3 vectors or non-immunized animals were also chal-
lenged with DENV-2. Mice were monitored the following
21 days for mortality and morbidity, regarding mainly the
development of hind leg paralysis. Three independent challenge
experiments were performed for each vaccine at the same
conditions, and data are summarized in Fig. 7.
Paralysis was detected 7 days after challenge in control
groups (pcTPA, pcDNA3 and non-immunized mice) and, in
the end of experiments, 90% of these animals presented
remarkable signs of dengue infection (Figs. 7a and c). In fact,
most of these mice died 21 days after challenge, with survival
rates of 33.3% in non-immunized or pcDNA3-inoculated
groups and of 50% in pcTPA-injected animals (differences not
significant, p=0.19043) (Figs. 7b and d). In contrast,
pcTPANS1- and pcENS1-vaccinated animals showed a consid-
erable reduction in clinical signs, with morbidity rates of 10% (3/
417S.M. Costa et al. / Virology 358 (2007) 413–42330) and 27% (8/30), respectively (significance with p<0.00001
in both cases, when compared to control groups) (Figs. 7a and c).
A strong correlation was observed between morbidity and sur-
vival rates. Indeed, both tested vaccines were highly protectiveFig. 5. Individual NS1-specific IgG response elicited in mice immunized with
(a) pcTPANS1, (b) pcENS1 and (c) pcENS1ANC. Animals were i.m. inoculated
with two DNA doses, blood samples were taken 4 weeks after the first
immunization and tested by ELISA. Serum samples harvested from mice
inoculated with control vectors pcTPA or pcDNA3 were pooled. Titers were
established as the reciprocal serum dilutions which gave an absorbance above
that of preimmune sera. Data represent the mean of duplicate values for each
sample, and bars are standard deviation of the mean.
Fig. 4. Electron microscopy of transfected BHK cells, immunolabeled with
DENV-2 hyperimmune mouse ascitic fluid and anti-mouse colloidal gold
conjugated IgG. Cells transfected with: (a) pcTPANS1, scale bar=0.45 μm; (b)
pcENS1, scale bar=0.22 μm; (c) pcENS1ANC, scale bar=0.21 μm; (d)
pcENS1ANC, scale bar=0.14 μm. Note the NS1 protein present in vesicles
(arrow), anchored to plasmamembrane (arrowhead) andNS1 containing vesicles
fused to cytoplasmic membrane (asterisk).against DENV-2, in which 96.7% (29/30) and 86.7% (26/30) of
pcTPANS1- and pcENS1-immunized mice, respectively, sur-
vived to challenge (significance with p=0.00004 for pcTPANS1
and p=0.00003 for pcENS1, when compared to control groups)
(Figs. 7b and d). Results revealed that the pcTPANS1 plasmid
was slightly more protective than the pcENS1, although not
statistically significant, regarding either survival (96.7% for
pcTPANS1 and 86.7% for pcENS1, p=0.16113) or morbidity
rates (10% for pcTPANS1 and 27% for pcENS1, p=0.09527).
Besides, in pcENS1-immunized group, paralysis was noted on
the 7th day after challenge, while in animals vaccinated with the
pcTPANS1, clinical infection signs appeared only on the 9th
day.
Antibody response in vaccinated animals after challenge
Levels of NS1-specific antibody increased more than 5 times
after challenge with DENV-2 in both vaccinated animals (titers
ranging from approximately 32,000 or 25,000 before challenge
to 254,000 or 140,000 after virus inoculation in pcTPANS1- and
pcENS1-immunized mice, respectively) (Fig. 8). In contrast,
control animals presented considerable low levels of NS1-
Fig. 6. Time course of serum IgG response to NS1 protein from Balb/c mice i.m.
immunized with two doses of pcTPANS1, pcENS1 or pcENS1ANC. Titers were
determined in ELISA using purified intact or heat-denatured NS1 protein
expressed in insect cells, as solid-phase bound antigen. Data represent the mean
of duplicate values of pooled serum samples harvested from immunized mice.
Arrows indicate time point of DNA inoculations. Standard deviations were
always under 10% of the mean value.
418 S.M. Costa et al. / Virology 358 (2007) 413–423specific IgG after challenge (titers ranging from 30,000 to
50,000) (data not shown).
The percentage of NS1-specific IgG1 and IgG2a subclasses
was then analyzed in the two vaccinated mouse groups and
controls. Mice immunized with the pcTPANS1 plasmid pre-Fig. 7. Percentage of morbidity (a, c) and survival (b, d) of Balb/c mice immunized w
Mice were i.m. immunized with two DNA doses and challenged 4 weeks after the f
followed the same virus infection procedure. Mice were daily monitored, and path
compilation of three independent experiments, with groups of 10 animals in each tesented mainly IgG1 antibodies, either before or after virus
challenge (Fig. 9). On the other hand, immunization with the
pcENS1 elicited similar levels of both IgG subclasses, and such
pattern remained similar after challenge (Fig. 9). In control
animals (non-immunized or pcTPA-injected mice), inoculation
of DENV-2 by the i.c. route induced predominantly NS1-spe-
cific IgG2a.
Discussion
In an effort to develop an optimal DNA vaccine for dengue
virus based on the NS1 protein, in the present report, we
expanded our previous work with the pcTPANS1 plasmid,
which contains the DENV-2 NS1 region fused to t-PA signal
sequence (Costa et al., 2006a,b). Such construction was
compared to three other plasmids encoding the DENV-2 ns1
gene. In one construct (pcENS1), this gene was cloned in frame
with its natural leader sequence, present at the 3′ end of the
envelope gene. The same region present in the pcENS1 was
cloned in frame with the sequence coding the N-terminal
hydrophobic stretch of the NS2a protein in order to generate the
pcENS1ANC. Another plasmid was constructed with the
addition of such NS2a sequence downstream the ns1 gene in
the pcTPANS1, engendering the pcTPANS1ANC.
Expression of the recombinant NS1 protein in transfected
mammalian cells was significantly different, depending on
the plasmid used. The pcTPANS1, pcENS1 and pcENS1ANCith pcTPANS1 (a, b) and pcENS1 (c, d) and i.c. challenged with NGC DENV-2.
irst plasmid inoculation. Non-immunized and pcTPA or pcDNA3-injected mice
ological symptoms, mainly hind leg paralysis, were recorded. Data represent
st (n=30).
Fig. 9. NS1-specific IgG subclass responses in mice immunized with pcTPANS1
and pcENS1, before and after challenge with DENV-2. Animals were inoculated
with recombinant plasmids or control vector (pcTPA), and serum samples were
harvested and pooled as depicted in Fig. 8. Each column represents the relative
percentage of IgG1 and IgG2a subclasses in each analyzed sample.
Fig. 8. NS1-specific antibody response in pcTPANS1- and pcENS1-immunized
mice, before and after challenges with DENV-2. Mice were i.m. injected with
two DNA doses and challenged 4 weeks after the first plasmid inoculation.
Serum samples were collected 4 weeks after the first DNA immunization (before
challenge) and 21 days after virus inoculation (after challenge). Titers of NS1-
specific antibodies were determined in ELISA with purified NS1 protein
expressed in insect cells as solid-phase bound antigen and calculated as
described in Fig. 5. Data represent the mean of duplicate values for pooled blood
samples, and bars are standard deviation of the mean.
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transfected with the pcTPANS1ANC did not present any
recombinant protein, as revealed by immunofluorescence
analyses. Apparently, the two signal hydrophobic sequences
(t-PA and ANC) are incompatible. One possible reason for such
results is that the presence of these two sequences may change
the NS1 conformation, which prevented the correct protein
processing. The incorrect folding of the protein could then lead
to its accumulation inside the cell, which might be toxic and
consequently no viable pcTPANS1ANC-transfected cells could
be detected. In addition to the intracellular NS1 detected in cells
transfected with the three other plasmids, this protein was also
identified in Western blot of culture supernatant as dimeric
forms. These results indicate that both homologous and hetero-
logous secretory signal sequences were efficient for targeting
translocation of protein into the endoplasmic reticulum. Further-
more, the presence of secreted dimeric forms of NS1 suggests
that this recombinant protein was expressed similarly to the
protein observed in DENV infected mammalian cells, in which
dimerization is essential for its export along the secretory
pathway to the plasma membrane (Pryor and Wright, 1993).
Moreover, the NS1 contains two conserved N-glycosylation
sites and it was demonstrated that the addition of sugar groups to
this protein contributes to dimer stability, increasing its hydro-
phobicity (Flamand et al., 1999; Pryor and Wright, 1994). Thus,
secretion of the NS1 by cells transfected with the pcTPANS1,
pcENS1 and pcENS1ANC plasmids as dimers suggests that
these proteins are glycosylated.
Electron microscopy analyses of pcTPANS1-, pcENS1- and
pcENS1ANC-transfected cells showed that the NS1 was found
mainly in cytoplasmic vesicles in the three cases. Such results
were consistent with the detection of NS1 in culture super-
natants, indicating that most protein is in fact target to the secre-
tory pathway. Furthermore, in pcENS1ANC-transfected cells,the NS1 was also found anchored to plasma membrane or
reaching the cell surface via membrane-bound vesicles. These
data confirm previous evidences that the NH2 terminus of the
NS2a protein is in fact required for association of the NS1 to cell
membrane, probably via GPI linkage (Jacobs et al., 2000).
All Balb/c mice inoculated with pcTPANS1 or pcENS1
developed a homogeneous humoral immune response with high
NS1-specific antibody levels. In contrast, only few pcEN-
S1ANC-immunized animals presented NS1-specific antibodies,
with heterogeneous levels, in which highest titers were approx-
imately six-fold lower than those found in mice inoculated with
the two other plasmids. Such results might be due to differences
in the NS1 expression patterns since part of the recombinant
protein should be retained in plasma membrane of in vivo
pcENS1ANC-transfected cells, similar to data observed in the in
vitro transfections. Consequently, the amount of soluble NS1
available for the immune system to elicit antibodies might be
diminished in these animals. These findings are partially in
agreement with other studies using recombinant vaccinia virus
expressing the DENV-4 NS1 protein and 15% of the NS2a
(Falgout et al., 1990). Animals immunized with such virus
presented low titers of NS1-specific antibodies, which correlated
to a partial protection against DENV-4. However, in this case,
authors observed that the expressed recombinant NS1 was not
correctly cleaved, leading to aberrant forms of the protein
(Falgout et al., 1990). On the other hand, our expression analysis
results showed that the NS1 was secreted as dimeric forms by
cells transfected with the three plasmids (pcTPANS1, pcENS1
and pcENS1ANC), similarly confirming the correct process of
the recombinant protein. Consistent with these findings,
antibodies induced by such plasmids recognized mainly intact
NS1 expressed in insect cells, while the reaction was significant
weakly detected when the protein was heat-denatured, with titers
more than 30-fold lower even for pcENS1ANC-elicited
antibodies, during peak IgG level. Such observations indicate
that these antibodies were predominantly directed to conforma-
tional surface-exposed epitopes and confirmed that all the three
recombinant NS1 expressed in vivo presented a tri-dimensional
420 S.M. Costa et al. / Virology 358 (2007) 413–423structure similar to the native viral protein, as previously sug-
gested (Costa et al., 2006b).
The protective ability of pcTPANS1 and pcENS1 immuniza-
tions was investigated in challenge experiments with Balb/c i.c.
injected with a mouse brain adapted NGC DENV-2. The
pcENS1ANC plasmid was not used in these challenge assays
due to the heterogeneous and low NS1-specific antibody
response it elicited. Our results revealed that the pcTPANS1
and pcENS1 plasmids conferred high level of protection. These
data are consistent with previous studies supporting that the
flavivirus NS1 by itself is able to elicit protective immunity
(Costa et al., 2006a,b; Falgout et al., 1990; Lin et al., 1998;
Schlesinger et al., 1987; Wu et al., 2003). Although not statis-
tically significant, the pcTPANS1 plasmid was slightly more
protective than the pcENS1, regarding survival and mainly
morbidity rates. Clinical infection signs appeared 2 days early,
on the 7th day after challenge, in pcENS1-immunized mice
(similar to control groups) when compared to what happened in
pcTPANS1-inoculated animals, which presented such signs on
the 9th day. In addition, morbidity rates 21 days post virus
inoculation were almost 3 times higher in pcENS1- than in
pcTPANS1-vaccinated animals (27% and 10% in pcENS1 and
pcTPANS1 groups, respectively). Furthermore, morbidity and
mortality rates varied among the three challenge experiments in
pcENS1-immunized mice, while vaccination with the
pcTPANS1 induced a considerable homogeneous protection in
all performed tests (data not shown). These results confirmed our
previous report with the pcTPANS1 plasmid (Costa et al.,
2006b) and other studies with a DNAvaccine encoding the NS1
and the signal peptide derived from C-terminus of the E protein
(Wu et al., 2003). The DNAvaccine constructed in Taiwan (Wu
et al., 2003) is very similar to the pcENS1, although the signal
peptide contains 19 amino acids, while in the case of the
pcENS1, this signal sequence is composed of 21 amino acids.
Besides, the ns1 gene cloned in the pcENS1 was amplified from
the NGC DENV-2 and in the other plasmid this gene came from
a Taiwanese DENV-2 strain. Immunization with the plasmid
DNA constructed in Taiwan also induces protection against
DENV-2, but in lower level (28% of mortality and 30% of
morbidity) when compared to the pcTPANS1 (3.3% of mortality
and 10% of morbidity), and similar to the pcENS1 (13.3% of
mortality and 27% of morbidity). Such observations are in
agreement with other findings, which demonstrate that the t-PA
signal sequence is a highly efficient signal peptide for induction
of strong immune responses by DNA vaccines against several
pathogens (Alves et al., 2001; Ashok and Rangarajan, 2002; Li
et al., 1999).
Animals vaccinated with the pcTPANS1 or pcENS1 exhi-
bited a significant increase of NS1-specific antibody levels after
virus challenge, indicating the activation of an immunological
memory with a rapid and strong secondary immune response.
These data also demonstrated that the protective immunity
induced by the NS1-based DNA vaccines were not sterilizing.
Such results were not surprising since the NS1 is not present in
the virion, and therefore the immune response against this
protein can only be protective after initial virus replication in
host cells. Supporting this fact, antibodies raised against NS1 byimmunizations with our DNA vaccines presented no detectable
neutralizing activity (data not shown).
The analyses of NS1-specific IgG subclasses elicited by both
DNA vaccines pcTPANS1 and pcENS1 revealed distinct
activation patterns of the immune system. Mice vaccinated
with pcTPANS1 developed a predominant anti-NS1 IgG1 sub-
class response (more than 80%), while pcENS1 immunization
elicited a mix of IgG1 and IgG2a (approximately 50%), before
and after virus challenge. In contrast, after the DENV-2 ino-
culation, animals in control groups (non-immunized or pcTPA-
injected) presented mainly NS1-specific IgG2a antibodies
(approximately 80%). Previous reports suggested that the NS1
can be protective against flavivirus infections due to the
induction of antibodies that kill infected target cells in a
complement-dependent manner (Henchal et al., 1988; Lin et al.,
1998). However, our results, concerning IgG subclass differ-
ences, cannot specify whether the complement activation is in
fact the major mechanism involved in the protection induced by
the pcTPANS1 and pcENS1 plasmids. The IgG2a subclass is
generally associated with substantial complement fixing activity
(Leatherbarrow and Dwek, 1984), although some studies have
demonstrated that IgG1 is also efficient in complement acti-
vating. In humans, the IgG1 subclass was shown to be a good
activator of the classical pathway while IgG2 was the best
subclass for the alternative pathway complement activation
(Lucisano and Lachmann, 1991). On the other hand, Chung et al.
(2006) demonstrated that different monoclonal antibodies
against the NS1 protein from West Nile virus can be protective
through different mechanisms, in a complement independent
pathway. Furthermore, the protective effect of these antibodies
was not dependent on the IgG subclass. Thus, it is probable that
mechanisms other than complement fixing might also play
account for the protection induced by anti-NS1 antibodies.
Besides, our results also suggest that the pcTPANS1 activated a
major Th2-type immune response and the pcENS1 immuniza-
tion led to an equilibrium of the two population cells (Th1 and
Th2), while survived animals in control groups, which presented
high paralysis signs, generated a drastically Th1 biased immune
response. Therefore, we cannot discard a possible contribution
of these cellular immune responses, as well as related cytokines,
to the induced protection. Further studies will be necessary in
order to evaluate such questions.
Materials and methods
Virus and cell lines
The dengue 2 virus (DENV-2) strain New Guinea C (NGC
DENV-2) was used for cloning the NS1 sequence and challenge
assays. NGC DENV-2 propagation was carried out in Vero cells
cultivated in medium 199 with Earle salts (E199) buffered with
sodium bicarbonate (Sigma, USA), supplemented with 10%
fetal bovine serum (FBS). For in vitro transfection and recom-
binant NS1 protein expression analyses, baby hamster kidney
cells (BHK-21) were propagated in Dulbecco's Modified Eagle
Medium (DMEM) (Invitrogen, USA), supplemented with 5%
FBS.
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Four pcDNA3-based plasmids were constructed encoding
the NS1 sequence from DENV-2. Total RNA from cells infected
with the virus was extracted with Trizol (Invitrogen), according
to the manufacturer's protocol. The RNAwas used as template
for the synthesis of a cDNA performed by reverse transcriptase
M-MLV (Invitrogen) with the antisense primer 5′-CAT AAG
CTT ACA GAG GTT CCC CCA TG-3′, which hybridizes to
nucleotides 5943 to 5958 in the NGC DENV-2 genome. Diffe-
rent segments containing the NS1 sequence were then amplified
by PCR using primers shown in Table 1. All sense and antisense
primers contained EcoRV and XhoI restriction sites, respect-
ively. The different PCR products were electrophoresed on a 1%
agarose gel, recovered with glass beads, geneclean (Stratagene,
USA), restricted with EcoRVand XhoI and ligated to the vectors
previously digested with the same enzymes. The pcDNA3
vector (Invitrogen) was used for construction of pcENS1 and
pcENS1ANC, while the plasmids pcTPANS1 and pcTPAN-
S1ANC were constructed based on the pcTPA, a modified
pcDNA3 vector that contains the human tissue plasminogen
activator (t-PA) signal sequence (Costa et al., 2006b). All
recombinant plasmids were screened by restriction mapping and
confirmed by sequencing, using ABI PRISM dye terminator
cycle sequencing core kit (Applied Biosystems, USA). Plasmids
were isolated from transformed Escherichia coli, DH5α strain,
and purified by Qiagen Plasmid Giga Kit (Qiagen, Germany),
following manufacturer's instruction. DNA concentrations were
determined by measuring optical density at 260 nm, and inte-
grity of plasmids was checked by agarose gel electrophoresis.
Plasmids were suspended in sterile water and stored at −20 °C
until use.
Transfection of BHK cells with different plasmids
BHK cells were transiently transfected with each recombi-
nant plasmid or with control vectors (pDNA3 or pcTPA) and
fixed or harvested 24 h after transfections. For detection of the
NS1 protein by immunofluorescence, 2×104 cells/well were
plated in chamber slides (Nunc, Denmark) with Optimen me-
dium (Invitrogen) and transfected with 0.2 μg of each DNA,Table 1
Primers used for amplifications of different DENV-2 NS1 sequences and constructio
Vectors a Primers Amplif
pcTPA 5′-GGGGGATATCGATAGTGGTTGCGTTG-3′ c NS1 (2
5′-GGGGCTCGAGTTAGGCTGTGACCAAG-3′ d
pcTPA 5′-GGGGGATATCGATAGTGGTTGCGTTG-3′c NS1 (2
5′-GGGGCTCGAGTTACCCTGTGATCAATG-3′d
pcDNA3 5′-GGGGGATATCATGCTGTCTGTGTCACTAG-3′c E (2359
5′-GGGGCTCGAGTTAGGCTGTGACCAAG-3′d
pcDNA3 5′-GGGGGATATCATGCTGTCTGTGTCACTAG-3′c E (2359
5′-GGGGCTCGAGTTACCCTGTGATCAATG-3′d
a Vectors used for cloning.
b Genome coordinates (Irie et al., 1989).
c Sense primer.
d Antisense primer.using lipofectamine (Invitrogen) under conditions suggested by
the manufacturer. For Western blot and electron microscopy
analyses, 5×105 cells were plated in 25 cm2 bottle and
transfected with 2 μg of DNA.
Immunofluorescence
Monolayers of transfected cells were washed in 0.1 M
phosphate buffer pH 7.4 (PB), fixed in 4% paraformaldehyde
in PB for 10 min, washed again in PB, permeabilized with
0.6% saponin in PB for 10 min and blocked with 1% bovine
serum albumin (BSA) and 0.2% saponin in PB for 15 min.
All such steps were conducted at room temperature. Cells
were then incubated with DENV-2 hyperimmune mouse
ascitic fluid (ATCC, USA) at a dilution of 1:1500 in PB for
1 h at 37 °C, washed tree times with PB and another incu-
bation of 1 h at 37 °C with fluorescein-conjugated goat anti-
mouse IgG (Southern Biotechnology, USA) diluted 1:100 in
PB. Slides were mounted with Vectashield medium (Vector
Laboratories Inc., USA), and cells were visualized in a fluo-
rescence microscope.
Western blotting
Western blotting of transfected whole-cell extracts and
culture supernatants was performed as previously described
(Costa et al., 2006b). Briefly, cell extracts were suspended in
SDS-PAGE sample buffer (Sambrook et al., 1989) and boiled
for 5 min. Culture supernatants were clarified by low speed
centrifugation, concentrated with Centricon YM-3 (Millipore
Corporation, USA), mixed with equal volume of SDS-PAGE
sample buffer without 2-mercaptoethanol and submitted or not
to heat treatment (boiled for 5 min). Proteins were sorted in
SDS-PAGE and transferred onto nitrocellulose membranes.
Dimeric and monomeric forms of NS1 were detected with
DENV-2 hyperimmune mouse ascitic fluid at a dilution of
1:1000 followed by incubation with rabbit anti-mouse immu-
noglobulin G conjugated to horseradish peroxidase (Southern
Biotechnology) diluted 1:4000. Membranes were developed
with the ECL kit (Amersham Biosciences, UK) and exposed to
Kodak X Omat films.n of recombinant plasmids
ied regions b Recombinant plasmids
422–3477) pcTPANS1
422–3477)+NS2a (3478–3615) pcTPANS1ANC
–2421)+NS1 (2422–3477) pcENS1
–2421)+NS1 (2422–3477)+NS2a (3478–3615) pcENS1ANC
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Monolayers of transfected cells were fixed overnight with 1%
glutaraldehyde in 0.2 M cacodylate buffer, pH 7.2. Cells were
then scraped, washed with the cacodylate buffer, dehydrated
with ethanol and embedded in LR Gold resin (London Resin
Company Ltda, England). Ultrathin sections (60–70 nm) were
collected on gold grids (400 mesh) and incubated for 1 h at room
temperature with DENV-2 hyperimmune mouse ascitic fluid,
diluted 1:1500 in 0.1 M Tris–HCl buffer, pH 7.4, with 0.1%
gelatin, 1% Tween-20 and 1%BSA. Grids were washed in water
and incubated for 1 h at room temperature with goat anti-mouse
colloidal gold conjugated IgG, 10 nm, (Sigma) diluted 1:40 in
the same buffer. Sections were washed in water, double stained
with uranyl acetate and lead citrate, washed again in water and
observed in a transmission electron microscope (EM 10, Zeiss,
Germany).
Immunization procedure
Experiments with mice were conducted in compliance with
Ethical Principles in Animal Experimentation stated in the
Brazilian College of Animal Experimentation and approved by
the Institute's Animal Use Ethical Committee. Balb/c mice, 4 to
6 weeks old, were inoculated by the intramuscular (i.m.) route
with 50 μg of plasmid dissolved in 50 μL of phosphate buffer
saline (PBS) in each tibialis posterior muscles (100 μg/mice)
using 27-gauge needles. Each animal group (n=10) received
two doses of one recombinant plasmid or control vector, given
2 weeks apart. For time course of NS1-specific antibody res-
ponse evaluation, animals were bled by retro-orbital puncture,
before inoculation (preimmune sera) and at several time
intervals after immunization. Initially, serum samples were
individually tested for reactivity against NS1 protein and then
pooled and stored at −20 °C for subsequent analyses. For chal-
lenge experiments, mice were bled 4 weeks after the first DNA
dose and at the end of experiments (21 days after challenge),
when animals were sacrificed.
Evaluation of NS1-specific antibody response
Mouse sera were tested for the presence of NS1-specific
antibodies by enzyme-linked immunosorbent assay (ELISA).
Wells of MaxiSorp plates (Nunc) were coated for 1 h at 37 °C
with 0.1 μg (in 100 μL PBS) of a recombinant DENV-2 NS1
protein expressed in insect cells (Hawaii Biotechnology Group
Inc., USA) and blocked overnight at 4 °C with 2% skim milk in
0.05% Tween-20–PBS (PBST). Assays were performed either
with intact or heat-denatured (boiled for 5 min) recombinant
NS1 protein. Serum samples were serially diluted and added to
wells previously washed with PBST. After 1 h at 37 °C, plates
were washed with PBST and incubated with goat anti-mouse
immunoglobulins IgG, IgG1 or IgG2a conjugated with horse-
radish peroxidase (Southern Biotechnology) for 1 h at 37 °C.
The secondary antibodies used to determine IgG subclasses were
highly specific and had quantitatively similar reactivity in
ELISA, thus allowing direct comparison between the levels ofeach subclass (Alves et al., 1998b). Reactions were measured at
A450 nm with ortho-phenylenediamine dihydrochloride (Sigma)
and H2O2 as substrate and with a 9 N H2SO4 stopping solution.
Titers were established as the reciprocal of serum dilution, which
gave an absorbance above that of the respective preimmune
serum.
DENV-2 challenge in mice
Two weeks after the second DNA dose, mice i.m. immunized
with recombinant or control plasmids were challenged with the
NGC DENV-2, a mouse brain adapted virus. Animals were
anesthetized with a mixture of ketamine-xylazine (Erhardt et al.,
1984) and intracerebrally (i.c.) inoculated with 30 μL of 4.32
log10 PFU of DENV-2, which corresponds to 3.8 LD50, diluted
in E199 medium supplemented with 5% FCS. Immediately after
the challenge procedure, inoculumwas back-titered in Vero cells
as described previously (Caufour et al., 2001). Mice were
separated in five groups (n=10) for each test: pcTPANS1-,
pcTPA-, pcENS1- and pcDNA3-inoculated mice and non-
immunized animals, all challenged with the same virus sample.
Animals were monitored for 21 days. Morbidity, mainly the
appearance of hind leg paralysis, and mortality were recorded.
After 21 days, survived animals were sacrificed and blood
samples were collected. Three independent challenge tests were
performed in the same experimental conditions.
Statistical analysis
Experimental results on challenge tests were analyzed for
their statistical significance by chi-square test.
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